TREATING CANCER
This document relates to methods and materials involved in treating cancer (e.g., melanoma). For example, methods and materials involved in using an anti-chronic inflammation treatment (e.g., chemotherapy) in combination with a cancer treatment agent (e.g., a cancer vaccine) to treat cancer are provided.
1 . A method for treating a mammal having cancer, said method comprising:
(a) administering to said mammal an anti-chronic inflammation treatment under conditions wherein the level of global chronic inflammation in said mammal is reduced, and
(b) administering to said mammal a cancer treatment agent under conditions wherein the presence of said cancer is reduced.
2 . The method of claim 1 , wherein said mammal is a human.
3 . The method of claim 1 , wherein said cancer is melanoma.
4 . The method of claim 1 , wherein said cancer is stage IV melanoma.
5 . The method of claim 1 , wherein said anti-chronic inflammation treatment comprises chemotherapy, radiation, an anti-IL-4 agent, an anti-IL-13 agent, or a steroid treatment.
6 . The method of claim 1 , wherein said cancer treatment agent is a cancer vaccine.
7 . The method of claim 1 , wherein said cancer vaccine is a MART-1, gp100, or survivin cancer vaccine.
8 . The method of claim 1 , wherein the period of time between the last administration of said anti-chronic inflammation treatment and the first administration of said cancer treatment agent is between two weeks and six months.
9 . A method for treating a mammal having cancer, said method comprising:
(a) administering to said mammal an anti-TGFβ antibody under conditions wherein the level of global chronic inflammation in said mammal is reduced, and
(b) administering to said mammal a cancer treatment agent under conditions wherein the presence of said cancer is reduced.
10 . The method of claim 9 , wherein said mammal is a human.
11 . The method of claim 9 , wherein said cancer is melanoma.
12 . The method of claim 9 , wherein said cancer is stage IV melanoma.
13 . The method of claim 9 , wherein said cancer treatment agent is a cancer vaccine.
14 . The method of claim 9 , wherein said cancer vaccine is a MART-1, gp100, or survivin cancer vaccine.
15 . The method of claim 9 , wherein the period of time between the last administration of said anti-TGFβ antibody and the first administration of said cancer treatment agent is between two weeks and six months.